Zobrazeno 1 - 10
of 457
pro vyhledávání: '"S Lipkowitz"'
Autor:
Ogo Egbuna, Brandon Zimmerman, George Manos, Anne Fortier, Madalina C. Chirieac, Leslie A. Dakin, David J. Friedman, Kate Bramham, Kirk Campbell, Bertrand Knebelmann, Laura Barisoni, Ronald J. Falk, Debbie S. Gipson, Michael S. Lipkowitz, Akinlolu Ojo, Mark E. Bunnage, Martin R. Pollak, David Altshuler, Glenn M. Chertow
Publikováno v:
New England Journal of Medicine. 388:969-979
Autor:
Elaine Ku, Raymond K. Hsu, Delphine S. Tuot, Se Ri Bae, Michael S. Lipkowitz, Miroslaw J. Smogorzewski, Barbara A. Grimes, Matthew R. Weir
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 9 (2019)
Background Obtaining 24‐hour ambulatory blood pressure (BP) is recommended for the detection of masked or white‐coat hypertension. Our objective was to determine whether the magnitude of the difference between ambulatory and clinic BPs has progno
Externí odkaz:
https://doaj.org/article/172a1fc1ec134359b708a8adb060d09f
Autor:
S. Lipkowitz
This work is devoted to therapies that take advantage of molecular targets relevant to breast cancer - so called novel molecular therapies. It presents a sampling of both old and new molecularly targeted therapies that are being developed.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ersoy Subasi, Munevver Mine Subasi, Peter L. Hammer, John Roboz, Victor Anbalagan, Michael S. Lipkowitz
Publikováno v:
Frontiers in Medicine, Vol 4 (2017)
The African American Study of Kidney Disease and Hypertension (AASK), a randomized double-blinded treatment trial, was motivated by the high rate of hypertension-related renal disease in the African-American population and the scarcity of effective t
Externí odkaz:
https://doaj.org/article/c3a6c0295cf74116bb3a70d7d7bea3b1
Autor:
Enrico Benedetti, Arjang Djamali, Madeleine M. Waldram, Kenneth L. Brayman, Stanley C. Jordan, Michael A. Rees, Jacqueline Garonzik-Wang, Lloyd E. Ratner, Matthew Cooper, Eliot Heher, Robert A. Montgomery, Jane J. Long, Jose Oberholzer, Christopher L. Marsh, George S. Lipkowitz, Marc L. Melcher, Adel Bozorgzadeh, Ty B. Dunn, Karina Covarrubias, Mark D. Stegall, Jason R. Wellen, Ron Shapiro, Jennifer Verbesey, Babak J. Orandi, John P. Roberts, Jose M. El-Amm, Debra L. Sudan, Allan B. Massie, R. Pelletier, Bashir R. Sankari, David A. Gerber, Pooja Singh, Marc P. Posner, Kyle R. Jackson, Tomasz Kozlowski, Dorry L. Segev, Jennifer D. Motter, Francis L. Weng, Sandip Kapur, A. Osama Gaber, Beatrice P. Concepcion, J. Harold Helderman
Publikováno v:
Am J Transplant
Incompatible living donor kidney transplant recipients (ILDKTr) have pre-existing donor-specific antibody (DSA) that, despite desensitization, may persist or reappear with resulting consequences, including delayed graft function (DGF) and acute rejec
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Francis L. Weng, Jacqueline Garonzik-Wang, Matthew Cooper, Jane Long, Eliot Heher, Stanley C. Jordan, Jennifer D. Motter, George S. Lipkowitz, Michael A. Rees, John P. Roberts, Jennifer Verbesey, Pooja Singh, Sandip Kapur, Lloyd E. Ratner, Jennifer K. Chen, David A. Gerber, Tomasz Kozlowski, Mark D. Stegall, Madeleine M. Waldram, Bashir R. Sankari, Niraj M. Desai, Dorry L. Segev, A. Osama Gaber, Jose Oberholzer, Babak J. Orandi, Jose M. El-Amm, Jason R. Wellen, Debra L. Sudan, Adel Bozorgzadeh, R. Pelletier, Enrico Benedetti, Robert A. Montgomery, Mary G. Bowring, Kenneth L. Brayman, Kyle R. Jackson, Marc P. Posner, Beatrice P. Concepcion, J. Harold Helderman, Allan B. Massie, Ty B. Dunn, Christopher L. Marsh, Marc L. Melcher, Karina Covarrubias, Arjang Djamali, Ron Shapiro
Publikováno v:
Transplantation
BACKGROUND Desensitization protocols for HLA-incompatible living donor kidney transplantation (ILDKT) vary across centers. The impact of these, as well as other practice variations, on ILDKT outcomes remains unknown. METHODS We sought to quantify cen
Publikováno v:
Clinical Kidney Journal
Cardiovascular disease is a leading cause of morbidity and mortality and is becoming more prevalent as the population ages and risk factors increase. This is most apparent in the end-stage renal disease (ESRD) patient population. In part, this is due